Anaphylactic reaction to recombinant insulin-like growth factor-I.
作者信息
Torjusen Erika, Calderon Jose, Rivkees Scott A
机构信息
Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA.
出版信息
J Pediatr Endocrinol Metab. 2008 Apr;21(4):381-4. doi: 10.1515/jpem.2008.21.4.381.
PMID:18556970
Abstract
Mecasermin [rDNA] (Increlex; Tercica, Inc.) is recombinant insulin-like growth factor-I (IGF-I) that has been approved to treat growth failure in children with severe primary IGF-I deficiency. Serious allergic reactions related to Increlex therapy have not been reported. We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.
摘要
Zotero 插件